MedPath

Exemestane

Generic Name
Exemestane
Brand Names
Aromasin
Drug Type
Small Molecule
Chemical Formula
C20H24O2
CAS Number
107868-30-4
Unique Ingredient Identifier
NY22HMQ4BX

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background

Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

Indication

For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Associated Conditions
Stage I Breast Cancer, Refractory, advanced Breast cancer
Clinical Trials
Related News

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2
Recruiting
Conditions
Locally Advanced Unresectable HER2-Negative Breast Carcinoma
Metastatic HER2-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Diagnostic Imaging
Other: Fludeoxyglucose F-18
Biological: Gonadotropin-releasing Hormone Analog
Procedure: Positron Emission Tomography
Drug: Therapeutic Estradiol
First Posted Date
2023-12-21
Last Posted Date
2025-03-12
Lead Sponsor
University of Washington
Target Recruit Count
60
Registration Number
NCT06179303
Locations
🇺🇸

Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Phase 2
Suspended
Conditions
Adult Ovarian Granulosa Cell Tumor
Interventions
Procedure: Biospecimen Collection
Procedure: Chest Radiography
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
First Posted Date
2023-12-13
Last Posted Date
2025-04-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
37
Registration Number
NCT06169124
Locations
🇺🇸

West Michigan Cancer Center, Kalamazoo, Michigan, United States

🇺🇸

Ascension Borgess Cancer Center, Kalamazoo, Michigan, United States

🇺🇸

Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan, United States

and more 64 locations

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2
Active, not recruiting
Conditions
Advanced or Metastatic Breast Cancer
Interventions
Drug: PF-07220060 CDK4 inhibitor
First Posted Date
2023-10-27
Last Posted Date
2025-03-18
Lead Sponsor
Pfizer
Target Recruit Count
333
Registration Number
NCT06105632
Locations
🇦🇷

Fundación CORI para la Investigación y Prevención del Cáncer, La Rioja, Argentina

🇦🇷

COE (Centro Oncológico de Excelencia), San Juan, Argentina

🇦🇷

Sanatorio Norte, Santiago del Estero, Argentina

and more 218 locations

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Phase 2
Recruiting
Conditions
Ductal Carcinoma in Situ
Interventions
Drug: Anastrazole
First Posted Date
2023-10-10
Last Posted Date
2025-04-29
Lead Sponsor
QuantumLeap Healthcare Collaborative
Target Recruit Count
400
Registration Number
NCT06075953
Locations
🇺🇸

Berkeley Outpatient Center, Berkeley, California, United States

🇺🇸

UCSF, San Francisco, California, United States

🇺🇸

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

and more 5 locations

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Phase 3
Active, not recruiting
Conditions
Metastatic Breast Cancer
HER2 Negative Breast Carcinoma
Breast Cancer
Advanced Breast Cancer
ER Positive Breast Cancer
Interventions
First Posted Date
2023-08-30
Last Posted Date
2025-03-11
Lead Sponsor
Olema Pharmaceuticals, Inc.
Target Recruit Count
510
Registration Number
NCT06016738
Locations
🇬🇧

Clinical Trial Site, London, United Kingdom

🇲🇾

Clinical Trials Site, Sungai Petani, Kedah, Malaysia

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Phase 2
Active, not recruiting
Conditions
Early-stage Breast Cancer
Breast Cancer
High Risk Breast Carcinoma
Interventions
Drug: LHRH Agonist
First Posted Date
2023-08-21
Last Posted Date
2024-11-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
90
Registration Number
NCT06001762
Locations
🇺🇸

Stamford Hospital, Stamford, Connecticut, United States

🇺🇸

Eastern Maine Medical Center (Northern Light), Brewer, Maine, United States

🇺🇸

New England Cancer Specialists, Scarborough, Maine, United States

and more 9 locations

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase 3
Recruiting
Conditions
Breast Cancer, Early Breast Cancer
Interventions
First Posted Date
2023-07-19
Last Posted Date
2025-05-21
Lead Sponsor
AstraZeneca
Target Recruit Count
5500
Registration Number
NCT05952557
Locations
🇬🇧

Research Site, Whitchurch, United Kingdom

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

First Posted Date
2023-06-06
Last Posted Date
2024-02-08
Lead Sponsor
Fudan University
Target Recruit Count
766
Registration Number
NCT05891093
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China

🇨🇳

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China

🇨🇳

Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 12 locations

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Phase 3
Recruiting
Conditions
Early Breast Cancer
Interventions
Drug: Ansastrozole
First Posted Date
2023-04-24
Last Posted Date
2025-05-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
1400
Registration Number
NCT05827081
Locations
🇺🇸

Ocala Research Institute, Inc, Ocala, Florida, United States

🇺🇸

Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States

🇺🇸

Washington Hospital Center, Washington, District of Columbia, United States

and more 7 locations

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Phase 3
Recruiting
Conditions
Breast Cancer, Early Breast Cancer
Interventions
First Posted Date
2023-03-20
Last Posted Date
2025-05-18
Lead Sponsor
AstraZeneca
Target Recruit Count
4300
Registration Number
NCT05774951
Locations
🇻🇳

Research Site, Hue, Vietnam

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy